Pharvaris N.V. (PHVS:NASDAQ) closed at $31.11 on October 21, 2026, up 0.68% on the day. The stock trades 28.1% below its 52-week high of $43.25 and 48.0% above its 52-week low of $21.02. Over the past year, it gained 31.7%. Pharvaris N.V. is part of the Health Care sector.
In 252 trading sessions since October 20, 2025, PHVS closed higher on 118 days (47%). Its best day was December 3, 2025 (+21.75%) and its worst was April 23, 2026 (-9.15%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
Find more stocks like PHVS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.